Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orexo AB ( (SE:ORX) ) has issued an announcement.
Orexo AB’s Q1 2025 interim report reveals stable net revenues of SEK 146.2 million amidst a volatile market, though EBITDA decreased to SEK 5.9 million. The company showed positive clinical data for its nasal powder-based epinephrine product and converted future royalties for an endometriosis treatment into shares in Gesynta Pharma. Additionally, Orexo announced promising in-vivo data for an intranasal vaccine developed with Abera Bioscience, potentially enhancing its market position.
More about Orexo AB
Orexo AB is a commercial-stage pharmaceutical company that focuses on developing drugs using advanced drug delivery technologies. The company is committed to corporate responsibility principles in human rights, labor, environment, and anti-corruption.
Average Trading Volume: 15,287
Current Market Cap: SEK510.3M
For detailed information about ORX stock, go to TipRanks’ Stock Analysis page.